Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177468 | 0.82 | CYP2C19 (0.36) | CYP2C19PTGDR2HTR6KDM4EALDH1A1 | |
| SCHEMBL1050296 | 0.81 | CYP2C19 (0.45) | CYP2C19ENPP3ENPP1HTR6PKM | |
| SCHEMBL16050462 | 0.81 | CYP2C19 (0.45) | CYP2C19PTGDR2ENPP3ENPP1HTR6 | |
| SCHEMBL2105176 | 0.81 | CYP2C19 (0.45) | CYP2C19PTGDR2ENPP3ENPP1HTR6 | |
| SCHEMBL16186392 | 0.80 | PTGDR2 (0.33) | CYP2C19PTGDR2LRRK2HTR6PKM | |
| SCHEMBL16178277 | 0.78 | LRRK2 (0.40) | CYP2C19LRRK2HTR6METKDM4E | |
| SCHEMBL27815784 | 0.78 | CYP2C19 (0.42) | CYP2C19PTGDR2ENPP3ENPP1HTR6 | |
| SCHEMBL2237471 | 0.77 | LMNA (0.51) | CYP2C19PTGDR2ENPP3ENPP1HTR6 | |
| Pyrimidine SCHEMBL27835166 | 0.76 | CYP2C19 (0.40) | CYP2C19PTGDR2ENPP3ENPP1HTR6 | |
| SCHEMBL28161675 | 0.76 | CYP2C19 (0.40) | CYP2C19PTGDR2ENPP3ENPP1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986608-B1 | ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS | H LUNDBECK AS (DK) | 2017-08-23 | — | — | EP | disclosed |
| US-9675594-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2017-06-13 | — | — | US | disclosed |
| US-9675594-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2017-06-13 | — | — | US | disclosed |
| US-20170020850-A1 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors | H. Lundebck A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| US-20170020850-A1 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors | H. Lundebck A/S (DK) | 2017-01-26 | — | — | US | disclosed |
| US-9499542-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-11-22 | — | — | US | disclosed |
| US-9499542-B2 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-11-22 | — | — | US | disclosed |
| US-20160102089-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-14 | — | — | US | disclosed |
| US-20160102089-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2016-04-14 | — | — | US | disclosed |
| CN-105263930-A | Arylpyrrolopyridine derived compounds as lrrk2 inhibitors | LUNDBECK & CO AS H | 2016-01-20 | — | — | CN | disclosed |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | H. LUNDBECK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-102127078-A | Heterocyclic janus kinase 3 inhibitors | ASTELLAS PHARMA INC | 2011-07-20 | — | — | CN | disclosed |
| EP-2251341-A1 | Heterocyclic Janus kinase 3 inhibitors | Astellas Pharma Inc. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| CN-101223168-A | Heterocyclic JANUS kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | CN | disclosed |
| EP-1910358-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | Astellas Pharma Inc. (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007007919-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020850-A1 | Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors | LRRK2, PARK7, SNCA | CYP2C19 2498/4885PTGDR2 2582/4885LRRK2 1/4885 |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | CYP2C19 1448/4885PTGDR2 1630/4885LRRK2 444/4885 |
| US-20160102089-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | CYP2C19 2082/4885PTGDR2 2454/4885LRRK2 1/4885 |
| US-20140315901-A1 | Arylpyrrolopyridine derived compounds as LRRK2 inhibitors | LRRK2, PARK7, SNCA | CYP2C19 2177/4885PTGDR2 2698/4885LRRK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.